Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04436744
Title A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche

Her2-receptor negative breast cancer


Giredestrant + Palbociclib

Anastrozole + Palbociclib

Age Groups: adult | senior
Covered Countries USA | ESP | DEU

No variant requirements are available.